PD-L1 Expression in Triple-negative Breast Cancer—a Comparative Study of 3 Different Antibodies

Assessment of programmed death protein-ligand 1 (PD-L1) in triple-negative breast cancer (TNBC) has entered daily practice to identify patients eligible for treatment with immune checkpoint inhibitors. However, different antibodies and different cut-offs for PD-L1 positivity are used, and the interc...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlajnic, Tatjana, Baur, Fabienne, Soysal, Savas D., Weber, Walter P., Piscuoglio, Salvatore, Muenst, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983741/
https://www.ncbi.nlm.nih.gov/pubmed/36165931
http://dx.doi.org/10.1097/PAI.0000000000001062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983741/
https://www.ncbi.nlm.nih.gov/pubmed/36165931
http://dx.doi.org/10.1097/PAI.0000000000001062

Ejemplares similares